Alkem Laboratories is diversifying into medtech and CDMO services to find new growth engines beyond its core pharma business. While the company maintains a strong cash position, investors should note that these new segments have long gestation periods, which could pressure profit margins in the near term.
Alkem Laboratories is undergoing a strategic shift, moving away from a pure pharmaceutical focus toward medtech and Contract Development and Manufacturing Organization (CDMO) services. This transition is aimed at long-term growth, though it comes at a time when the company expects its earnings to grow at a compound annual rate of 10-12 percent over the next two years. Investors may view this as a phase of consolidation while the company builds these new revenue streams.
The company’s core domestic business remains its strongest foundation, contributing roughly 67 percent of total sales. Within India, Alkem is focusing more on the chronic segment, which accounts for about 22 percent of domestic revenue, as it seeks to improve margins compared to the more volatile acute care market. Meanwhile, the company’s trade generics business continues to navigate challenges like intense market competition and higher raw material costs. In the United States, price erosion has begun to stabilize, and the company is preparing to roll out products like generic Tolvaptan for kidney disease and an injectable version of semaglutide to maintain its market footprint.
A central part of this strategy is the recent acquisition of a 55 percent stake in the Swiss-based firm Occlutech Holdings for €99.4 million. This investment is designed to build a presence in the structural heart market, with commercial operations in the US expected by fiscal year 2028. Additionally, the company is building its CDMO capabilities, specifically for monoclonal antibodies. Since these new business units are currently in early development or clinical supply phases, they are not yet generating significant profit. The operational costs involved in scaling these projects are likely to exert downward pressure on overall profit margins in the coming years.
Despite these expenses, Alkem maintains a solid financial position, with a net cash balance of ₹5,400 crore as of March 2026. This liquidity provides the company with the flexibility to fund its long-term expansion plans without straining its base operations. Going forward, the most important monitorables for investors will be the speed at which these new medtech and CDMO projects reach commercial viability, the trend of profit margins as these costs are absorbed, and the company’s ability to manage competitive pressures in its core generics business.